ARTICLE | Preclinical News
Cyclerion's sGC activation could work for NASH
May 14, 2019 12:00 AM UTC
With new preclinical data in hand, Ironwood-spinout Cyclerion is making the case for extending its lead sGC stimulator praliciguat into NASH.
Cyclerion Therapeutics Inc. (NASDAQ:CYCN) completed its spinout from Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in April with a pipeline of five soluble guanylate cyclase (sGC) programs, including praliciguat, a systemic sGC stimulator in Phase II trials to treat diabetic nephropathy and heart failure preserved ejection fraction (HFpEF) (see "Ironwood Spinout Cyclerion Planning $175M Private Placement")...
BCIQ Target Profiles